Evidence map›Paper›PMID 37763082›Full record

ArticleJournal of personalized medicine2023

Cytotoxic Activity of Melatonin Alone and in Combination with Doxorubicin and/or Dexamethasone on Diffuse Large B-Cell Lymphoma Cells in In Vitro Conditions.

Sylwia Mańka, Piotr Smolewski, Barbara Cebula-Obrzut, Agata Majchrzak, Klaudia Szmejda, Magdalena Witkowska

Open access · goldAbstract read
In one paragraph

Article in Journal of personalized medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Sylwia MańkaDepartment of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland.ORCID 0000-0003-0314-2402
Piotr SmolewskiDepartment of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
Barbara Cebula-ObrzutDepartment of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland.ORCID 0000-0002-2689-7130
Agata MajchrzakDepartment of Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland.
Klaudia SzmejdaDepartment of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
Magdalena WitkowskaDepartment of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
Medical University of Lodz · PLCopernicus Memorial Hospital · PL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melatonin (MLT), a pineal gland hormone, not only regulates circadian and seasonal rhythms, but also plays an important role in many aspects of human physiology and pathophysiology. MLT is of great interest as a natural substance with anti-cancer activities. The aim of this study was to assess the cytotoxicity and apoptosis of MLT, used alone or in combination with one of the most active anti-cancer drugs, doxorubicin (DOX), and a well-known anti-inflammatory drug, dexamethasone (DEX), on a diffuse large B-cell lymphoma (DLBCL)-derived cell line. The cytotoxicity and cell cycle distribution were measured using propidium iodide staining, while apoptosis was assessed using the annexin-V binding method. Additionally, to elucidate the mechanisms of action, caspase-3, -8, and -9 and a decline in the mitochondrial potential were determined using flow cytometry. MLT inhibited cell viability as well as induced apoptosis and cell cycle arrest at the G0/G1 phase. The pro-apoptotic effect was exerted through both the mitochondrial and caspase-dependent pathways. Furthermore, we observed increased cytotoxic and pro-apoptotic activity as well as the modulation of the cell cycle after the combination of MLT with DOX, DEX, or a combination of DOX + DEX, compared with both drugs or MLT used alone. Our findings confirm that MLT is a promising in vitro anti-tumour agent that requires further evaluation when used with other drugs active against DLBCL.

Indexed as

apoptosiscell cycledexamethasonediffuse large B-cell lymphomadoxorubicinmelatonin

Identifiers

PMID37763082
PMCPMC10532635
OpenAlexW4386221201

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.